白血球特异癌/睪丸癌抗原（PRAME）是一种在体细胞组织和各种实体恶性肿瘤中选择性表达的癌/睪丸抗原，与预后不良相关。我们的研究旨在全面比较其在大样本的输卵管-卵巢上皮肿瘤中的表达情况，并检查其与我们的临床病理数据的相关性，以及评估其在诊断和治疗中的潜在应用。我们检查了485例上皮性输卵管-卵巢肿瘤，包括107例透明细胞癌（CCC），52例子宫内膜癌（EC），103例高级别浆液性癌（HGSC），119例低级别浆液性癌（LGSC）/浆液性边界肿瘤的微小乳头状变体（mSBT），以及104例黏液性癌（MC）/黏液性边界肿瘤（MBT）。免疫组化分析是使用TMAs进行的。EC（60%），HGSC（62%）和CCC（56%）显示了最高水平的表达，而LGSC/mSBT（4%）和MC/MBT（2%）的表达罕见。临床病理相关和生存分析结果显示无预后意义。我们的研究结果表明，在输卵管-卵巢上皮肿瘤的鉴别诊断中，PRAME既不具有预后意义，也不是一个合适的辅助标志物。然而，关于PRAME表达的知识可能在其潜在预测意义方面很重要，因为目前正在研究将PRAME作为潜在治疗选择的靶点。© 2023. 本文作者（作者自有版权），独家授权给德国斯普林格出版公司（Springer-Verlag GmbH）旗下的斯普林格自然出版集团（Springer Nature）。

Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.